A Bioequivalence Study of Injections of Mirikizumab Solution Using Investigational 1-mL and 2-mL Pre-Filled Syringes and Investigational 1-mL and 2-mL Autoinjectors in Healthy Participants
Latest Information Update: 18 Jul 2022
Price :
$35 *
At a glance
- Drugs Mirikizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 14 Jul 2022 Status changed from active, no longer recruiting to completed.
- 06 Apr 2022 Planned End Date changed from 30 May 2022 to 20 Jun 2022.
- 06 Apr 2022 Planned primary completion date changed from 30 May 2022 to 20 Jun 2022.